Literature DB >> 4083211

[Pre- and post-operative changes of serum proteins in renal cancer patients].

H Hisazumi, K Nakajima, A Nishino, T Misaki, S Migita.   

Abstract

Using a micro-single radial immunodiffusion method, quantitative studies have been made on the serum proteins of 30 renal cancer patients; 15 patients without metastasis and 15 patients with metastasis, and expressed by percentage of those obtained on 98 normal volunteers regarded as 100%. Of 45 proteins studied, 4 (Pre, Alb, alpha 2HS and Tf) significantly decreased and 10 (alpha 1AT, alpha 1AG, alpha 1X, Hp, Cp, C9, C5, beta 2III, C4 and C3PA) significantly increased before nephrectomy in both patient groups. In postoperative follow-up studies of the non-metastasis patient group, Pre, Alb and alpha 2HS increased, while alpha 1AT, alpha 1AG, Hp, C9, C5, beta 2III, C4 and C3PA decreased, and normal levels were attained within 6 months after nephrectomy. In the metastasis patient group, no significant changes of these serum proteins were observed. Serum proteins showing significant difference between the 2 patient groups were more prominent 6 months after nephrectomy, namely, the majority of the dysproteinemia caused by the presence of renal cancer did not disappear even 1 month after extirpation of the tumor. alpha 1AT was normalized 1 month after nephrectomy at a highly significant difference, P less than 0.001, and considered one of the promising proteins in terms of clinical course evaluation. As a new finding, renal cancer group with metastasis showed a decrease of FN postoperatively suggesting increase of a fibrin deposition and fibrinogen metabolism in cancer tissue.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4083211

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  1 in total

1.  A HIF1α-GPD1 feedforward loop inhibits the progression of renal clear cell carcinoma via mitochondrial function and lipid metabolism.

Authors:  Ren Liu; Yuanfa Feng; Yulin Deng; Zhihao Zou; Jianheng Ye; Zhiduan Cai; Xuejin Zhu; Yingke Liang; Jianming Lu; Hui Zhang; Yong Luo; Zhaodong Han; Yangjia Zhuo; Qingling Xie; Chi Tin Hon; Yuxiang Liang; Chin-Lee Wu; Weide Zhong
Journal:  J Exp Clin Cancer Res       Date:  2021-06-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.